HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
Stocks · News reference
BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media eventsStabilization of sleep
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.